Differences in dosing and patient characteristics may also play a role
Wall Street Analysts Goldman Sachs predicts that the oral GLP-1s (including oral Wegovy, Lillys orforglipron, and other pipeline products) will capture only a combined 24% of the GLP-1 market by 2030
As DLA Piper summed up: It is an important reminder that incorporating a human-in-the-loop to oversee, review, and approve all AI-generated outputs is key
Whether that's friends, family, groups, or ongoing medical contact, accountability helps you handle rough patches
In the highest-dose group, about 60 percent of participants lost at least 10 percent of their body weight, while 40 percent lost 15 percent or more
Trulicity (dulaglutide): Remains a reliable once-weekly diabetes option with cardiovascular risk-reduction language in its FDA labeling